Literature DB >> 30106578

Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Eric A Wold, Jianping Chen, Kathryn A Cunningham, Jia Zhou.   

Abstract

G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs. Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases. GPCR allosteric modulation is an innovative targeting approach that broadens the available small molecule toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clinical trials. Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development. This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chemistry approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30106578      PMCID: PMC6556150          DOI: 10.1021/acs.jmedchem.8b00875

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  277 in total

Review 1.  Biased signalling and allosteric machines: new vistas and challenges for drug discovery.

Authors:  Terry P Kenakin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Allosteric modulation of the cannabinoid CB1 receptor.

Authors:  Martin R Price; Gemma L Baillie; Adèle Thomas; Lesley A Stevenson; Morag Easson; Richard Goodwin; Adèle McLean; Lorraine McIntosh; Gillian Goodwin; Glenn Walker; Paul Westwood; Julia Marrs; Fiona Thomson; Phillip Cowley; Arthur Christopoulos; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2005-08-19       Impact factor: 4.436

Review 3.  International Union of Pharmacology. XLVI. G protein-coupled receptor list.

Authors:  Steven M Foord; Tom I Bonner; Richard R Neubig; Edward M Rosser; Jean-Phillipe Pin; Anthony P Davenport; Michael Spedding; Anthony J Harmar
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

4.  Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs.

Authors:  Ron O Dror; Hillary F Green; Celine Valant; David W Borhani; James R Valcourt; Albert C Pan; Daniel H Arlow; Meritxell Canals; J Robert Lane; Raphaël Rahmani; Jonathan B Baell; Patrick M Sexton; Arthur Christopoulos; David E Shaw
Journal:  Nature       Date:  2013-10-13       Impact factor: 49.962

5.  Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor.

Authors:  James M Salovich; Paige N Vinson; Douglas J Sheffler; Atin Lamsal; Thomas J Utley; Anna L Blobaum; Thomas M Bridges; Uyen Le; Carrie K Jones; Michael R Wood; J Scott Daniels; P Jeffrey Conn; Colleen M Niswender; Craig W Lindsley; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2012-06-06       Impact factor: 2.823

6.  Synthesis and biological evaluation of novel allosteric enhancers of the A1 adenosine receptor based on 2-amino-3-(4'-chlorobenzoyl)-4-substituted-5-arylethynyl thiophene.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Adriaan P IJzerman; Arnault Massink; Olga Cruz-Lopez; Luisa Carlota Lopez-Cara; Giulia Saponaro; Delia Preti; Mojgan Aghazadeh Tabrizi; Stefania Baraldi; Allan R Moorman; Fabrizio Vincenzi; Pier Andrea Borea; Katia Varani
Journal:  J Med Chem       Date:  2014-09-12       Impact factor: 7.446

Review 7.  "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology.

Authors:  Michael R Wood; Corey R Hopkins; John T Brogan; P Jeffrey Conn; Craig W Lindsley
Journal:  Biochemistry       Date:  2011-03-04       Impact factor: 3.162

8.  Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors.

Authors:  Carrie H Croy; Douglas A Schober; Hongling Xiao; Anne Quets; Arthur Christopoulos; Christian C Felder
Journal:  Mol Pharmacol       Date:  2014-05-07       Impact factor: 4.436

9.  Design and optimization of selective azaindole amide M1 positive allosteric modulators.

Authors:  Jennifer E Davoren; Steven V O'Neil; Dennis P Anderson; Michael A Brodney; Lois Chenard; Keith Dlugolenski; Jeremy R Edgerton; Michael Green; Michelle Garnsey; Sarah Grimwood; Anthony R Harris; Gregory W Kauffman; Erik LaChapelle; John T Lazzaro; Che-Wah Lee; Susan M Lotarski; Deane M Nason; R Scott Obach; Veronica Reinhart; Romelia Salomon-Ferrer; Stefanus J Steyn; Damien Webb; Jiangli Yan; Lei Zhang
Journal:  Bioorg Med Chem Lett       Date:  2015-11-17       Impact factor: 2.823

Review 10.  Biased and g protein-independent signaling of chemokine receptors.

Authors:  Anne Steen; Olav Larsen; Stefanie Thiele; Mette M Rosenkilde
Journal:  Front Immunol       Date:  2014-06-23       Impact factor: 7.561

View more
  24 in total

Review 1.  Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target.

Authors:  Na Ye; Bang Li; Qi Mao; Eric A Wold; Sheng Tian; John A Allen; Jia Zhou
Journal:  ACS Chem Neurosci       Date:  2018-12-20       Impact factor: 4.418

2.  The role of EP2 receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1.

Authors:  Jacques A Bertrand; David F Woodward; Joseph M Sherwood; Jenny W Wang; Darryl R Overby
Journal:  Br J Ophthalmol       Date:  2020-11-25       Impact factor: 4.638

3.  Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site.

Authors:  Zhiqing Liu; Yi Li; Haiying Chen; Hsien-Tsung Lai; Pingyuan Wang; Shwu-Yuan Wu; Eric A Wold; Paul G Leonard; Sarah Joseph; Haitao Hu; Cheng-Ming Chiang; Allan R Brasier; Bing Tian; Jia Zhou
Journal:  J Med Chem       Date:  2022-01-04       Impact factor: 7.446

Review 4.  Purinergic GPCR transmembrane residues involved in ligand recognition and dimerization.

Authors:  Veronica Salmaso; Shanu Jain; Kenneth A Jacobson
Journal:  Methods Cell Biol       Date:  2021-07-12       Impact factor: 1.829

5.  Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists.

Authors:  Pingyuan Wang; Daniel E Felsing; Haiying Chen; Sweta R Raval; John A Allen; Jia Zhou
Journal:  ACS Med Chem Lett       Date:  2019-04-05       Impact factor: 4.345

6.  Nucleic acid ligands act as a PAM and agonist depending on the intrinsic ligand binding state of P2RY2.

Authors:  Masaki Takahashi; Ryo Amano; Michiru Ozawa; Anna Martinez; Kazumasa Akita; Yoshikazu Nakamura
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-04       Impact factor: 11.205

7.  Repositioning Dequalinium as Potent Muscarinic Allosteric Ligand by Combining Virtual Screening Campaigns and Experimental Binding Assays.

Authors:  Angelica Mazzolari; Silvia Gervasoni; Alessandro Pedretti; Laura Fumagalli; Rosanna Matucci; Giulio Vistoli
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

Review 8.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

9.  Design, Synthesis and Characterization of a New Series of Fluorescent Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulators.

Authors:  Víctor Fernández-Dueñas; Mingcheng Qian; Josep Argerich; Carolina Amaral; Martijn D P Risseeuw; Serge Van Calenbergh; Francisco Ciruela
Journal:  Molecules       Date:  2020-03-27       Impact factor: 4.411

Review 10.  The Retinoid and Non-Retinoid Ligands of the Rod Visual G Protein-Coupled Receptor.

Authors:  Joseph T Ortega; Beata Jastrzebska
Journal:  Int J Mol Sci       Date:  2019-12-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.